Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors

2005 ◽  
Vol 66 (08) ◽  
pp. 974-981 ◽  
Author(s):  
Michael E. Thase ◽  
Barbara R. Haight ◽  
Nathalie Richard ◽  
Carol B. Rockett ◽  
Melinda Mitton ◽  
...  
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin ◽  
Remission Rates

scholarly journals Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

2001 ◽  
Vol 178 (3) ◽  
pp. 234-241 ◽  
Author(s):  
Michael E. Thase ◽  
A. Richard Entsuah ◽  
Richard L. Rudolph
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Depression Score ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Double Blind ◽  
Remission Rates ◽  
The Difference ◽  
Definition Of

BackgroundIt had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs).AimsTo compare remission rates during treatment with SSRIs or venlafaxine.MethodData from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score ≤ 7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine; n=748) or placebo (four studies; n=446).ResultsRemission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P < 0.001; odds ratio for remission is 1.50 (1.3–1.9), favouring venlafaxine v. SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission.ConclusionsRemission rates were significantly higher with venlafaxine than with an SSRI.

scholarly journals Antidepressants in the Practice of a Gastroenterologist

2021 ◽  
Vol 17 (4) ◽  
pp. 90-93
Author(s):  
L.D. Firsova ◽  
Keyword(s):  
Side Effects ◽  
Serotonin Reuptake ◽  
Digestive System ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Tricyclic Antidepressants ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin ◽  
Therapeutic Effects ◽  
Cardiovascular Pathology

Antidepressants are widely used in modern gastroenterology. The article discusses the indications for the prescribing antidepressants to the patients with disorders of the digestive system, examines the features of antidepressant therapy in the gastroenterological patients with comorbid cardiovascular pathology. The main groups of antidepressants (selective serotonin reuptake inhibitors and tricyclic antidepressants) are compared in terms of therapeutic effects and potential side effects

Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics

1998 ◽  
Vol 12 (4_suppl) ◽  
pp. 55-S87 ◽  
Author(s):  
Burton J. Goldstein ◽  
Paul J Goodnick
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Safety Margin ◽  
Antidepressant Drugs ◽  
Healthcare Services ◽  
Serotonin Reuptake Inhibitors ◽  
Antidepressant Therapy ◽  
Selective Serotonin

The clinical use of tricyclic antidepressants (TCAs) is often complicated by toxicity and safety problems due to their effects on multiple mechanisms of action, many of which are unnecessary for therapeutic effect. The development of the selective serotonin reuptake inhibitors (SSRIs), with their selective mode of action, has resulted in a class of antidepressant drugs possessing an improved side-effect profile, while retaining good clinical efficacy. Their introduction into clinical practice has led to enhanced patient compliance with antidepressant therapy and the ability to maintain treatment over longer periods of time at an adequate therapeutic dose. Although, as a result of their selective action, side-effects associated with SSRI therapy are minimised, distinct variations between individual SSRIs in terms of their tolerability profiles have been observed. The wealth of clinical data now available has revealed differences in their potential to cause psychiatric and neurological side-effects, dermatological reactions, anticholinergic side-effects, changes in body weight, sexual dysfunction, cognitive impairment, discontinuation reactions and drug-drug interactions. Patients who suffer from concomitant depression and physical illness may experience different tolerability profiles, in addition to the greater likelihood that they will be receiving concomitant medications with the potential for pharmacokinetic drug-drug interactions with coadministered SSRI therapy. In addition, the safety margin of SSRIs in overdose may vary within the group. Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients. A successful clinical outcome leads to a reduced economic burden for the patient, their family and the healthcare services. Thus, pharmacoeconomic considerations are also important in choosing antidepressant therapy. The SSRIs, despite relatively higher prescription costs, have been demonstrated to be a more cost-effective option than the TCAs. Furthermore, there is evidence that the emerging clinical differences between SSRIs may translate into significantly different economic outcomes within the group.

Sign in / Sign up

Export Citation Format

Share Document